Annovis Bio (ANVS) investor relations material

Executive summary

• Focused on late-stage clinical development of buntanetap for Alzheimer's and Parkinson's diseases, with pivotal Phase 3 trials ongoing and additional studies planned pending funding.

• No product revenue to date; operations funded primarily through equity offerings and warrant issuances.

• Accumulated deficit reached $181.3 million as of March 31, 2026, with continued net losses expected.

Financial highlights

• Net loss for Q1 2026 was $17.6 million, compared to $5.5 million in Q1 2025, driven by increased R&D expenses.

• Operating expenses rose to $18.0 million from $6.3 million year-over-year, mainly due to higher clinical trial costs.

• Cash and cash equivalents were $14.2 million at March 31, 2026, down from $19.5 million at year-end 2025.

• Net cash used in operating activities was $9.0 million for Q1 2026, up from $8.1 million in Q1 2025.

• Financing activities provided $3.7 million in Q1 2026, primarily from equity sales.

Outlook and guidance

• Current cash is expected to fund operations until Q4 2026; substantial additional capital will be needed for ongoing trials and commercialization.

• Management has concluded substantial doubt exists about the ability to continue as a going concern without new funding.

• Plans to raise additional capital through equity, debt, or other alternatives; may defer expenses if needed.